Great post Mozz. Appreciate the time you have put into this.
I would suggest PAR'S profit margins are going to be way higher than the three companies you have compared us with. Campbells looks to be the best of the lot with net income of $808mn on revenue of almost $9bn, roughly 10%.
Michael Collins estimated PAR might keep 50% on any revenue, this includes all taxes, expenses, etc. This isn't out of the question given the high margins afforded in the biotech sector. $5 bn will equate to roughly the $20 EPS that has been mentioned before. The numbers start to get really ridiculous!
The point is if PAR does hit $10bn of revenue it is going to be far more valuable than the other three companies. The share price will be in the hundreds.
I know you are being super conservative and enjoy reading your posts. Cheers
Great post Mozz. Appreciate the time you have put into this. I...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.015(7.50%) |
Mkt cap ! $75.30M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 20.0¢ | $175.5K | 833.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 8334 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |